Stock Price & Analysis

Based on the recent market data and analysis, here is a concise assessment of IDXX:

Technical Analysis

• Stock is showing a downward trend from its recent high of $576.29 on Feb 23rd
• Currently trading at $452.77, representing a significant decline
• Volume has been increasing during the downward movement, indicating strong selling pressure

Recent Insider Activity

• Multiple executives exercised options on Feb 14th, 2025
• Notable sales by key executives in early February:
  • CEO MAZELSKY sold 12,000 shares at $572.61
  • CFO MCKEON sold 23,326 shares at $570.01
  • Chief Revenue Officer FENNELL sold 8,198 shares at $573.87

Analyst Sentiment

• Current analyst consensus suggests a Moderate Buy
• Average price target of $519.50, indicating 14.7% upside potential from current levels
• Recent Hold rating from Bank of America with $535 target

Based on the technical weakness, significant insider selling, and current market conditions, selling IDXX at current levels appears to be the prudent action. The stock has broken below key support levels and shows continued selling pressure.

Based on the provided data and recent market developments, here's a price prediction analysis for IDXX stock in 2025:

Technical Analysis

The stock is currently trading at $452.77 as of February 21, 2025, showing a consolidation pattern after recent earnings-driven rally. Technical indicators suggest:

• RSI (14) at 55.20 indicates neutral momentum
• MACD showing positive trend with 6.34 value but weakening momentum (-1.18 histogram)
• Trading between Bollinger Bands (BBP: 0.54) suggests moderate upside potential

Fundamental Catalysts

Recent Q4 2024 results showed strong performance:

• Revenue grew 6% to $954.3 million
• EPS increased 13% to $2.62
• Strong Companion Animal Group growth of 6%

Analyst Consensus

According to recent analyst coverage:

• Average price target: $518.57
• Represents 14.5% upside from current levels
• Moderate Buy consensus rating
• Recent price target updates:
  • Piper Sandler: $510
  • Bank of America: $535
  • Barclays: $520

2025 Price Prediction

Based on technical analysis, fundamental growth drivers, and analyst consensus, IDXX stock is expected to reach $520-525 by end of 2025. This projection is supported by:

1. Company's strong execution in core business segments
2. Continued innovation with new product launches like Cancer Dx screening test
3. Healthy industry fundamentals in pet healthcare sector
4. Technical support levels and momentum indicators

The stock has potential to exceed this target if market conditions remain favorable and company maintains its growth trajectory.

The S1 support level for IDXX Stock is $444.51 ,The R1 resistant level for IDXX Stock is $464.91.

As of the end of day on 2025-02-26, the price of IDXX Stock was $462.89.

The target price for IDXX Stock according to analyst rating is 518.57, with the highest price target at 550.00 and the lowest at 460.00. Analysts have a Moderate Buy rating on IDXX Stock overall.

The market cap of IDXX is $37.4B.

Based on recent data and market performance, IDXX appears to be moderately overvalued at its current price of $452.77, trading at a P/E ratio of 55.16x which is significantly higher than industry averages. The company's recent Q4 2024 earnings beat expectations with strong revenue growth of 6% and EPS growth of 13%, but the current valuation multiples suggest the market has already priced in much of this growth potential. Technical indicators show the stock is trading near its 200-day moving average of $466.21, with RSI at 55.20 suggesting neutral momentum. While IDEXX maintains solid fundamentals with improving margins and strong recurring revenue from its CAG Diagnostics segment (80.18% of total revenue), the premium valuation creates limited upside potential at current levels.

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. Its Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. Its LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve the quality and safety of milk.

Based on the provided data and market research, here is the IDXX stock price prediction for 2030:

IDEXX Laboratories (IDXX) stock is projected to reach $819 by the end of 2030, representing an 81% increase from the current price of $452.77. This forecast is supported by several key factors:

The bullish prediction is driven by:

1. Strong Industry Growth: The pet industry is expected to reach nearly $500 billion by 2030, with the US remaining the largest market approaching $200 billion. IDEXX's dominant position in veterinary diagnostics positions it well to capture this growth.

2. Innovation Pipeline: The company is "on the front end of a new wave of major innovation" with products like the Cancer Dx screening test, indicating strong future growth potential.

3. Solid Financial Performance: Recent Q4 2024 results showed:

• Revenue growth of 6% to $954.3 million
• EPS growth of 13% to $2.62
• Strong operating margin expansion

The price target is based on:

• Continued market leadership in veterinary diagnostics
• Expanding profit margins through operational efficiency
• Growing recurring revenue streams from diagnostic services
• Increasing pet healthcare spending trends globally

IDXX has a total of 11000 employees.